FDA places partial clinical hold on Zentalis' cancer drug studies after two patient deaths.

Zentalis Pharmaceuticals shares fell after the FDA placed a partial clinical hold on three cancer drug studies. The drug, azenosertib, was being tested against solid tumors and in patients with ovarian and uterine cancer. The decision came after two patient deaths due to presumed sepsis in one of the studies. Zentalis remains committed to the azenosertib development program and plans to share additional data later this year.

June 18, 2024
10 Articles

Further Reading